Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
Ascendis Pharma (ASND) reported its Q4 and full year 2024 financial results, highlighting strong commercial performance. YORVIPATH achieved 908 prescriptions by Feb. 7, 2025, with full-year 2024 revenue of €28.7 million. SKYTROFA generated approximately €202 million in full-year revenue (excluding prior year adjustments).
The company's total revenue for 2024 reached €363.6 million, up from €266.7 million in 2023, driven by the €91.3 million ($100 million) upfront payment from Novo Nordisk and increased commercial product sales. Operating expenses totaled €598.1 million for 2024. The company reported a net loss of €378.1 million (€6.53 per share) for 2024.
Cash position stood at €559.5 million as of December 31, 2024, with an additional $100 million received from Novo Nordisk in January 2025. The company plans to submit an NDA for TransCon CNP in Q1 2025 for achondroplasia treatment in children.
Ascendis Pharma (ASND) ha riportato i risultati finanziari del quarto trimestre e dell'intero anno 2024, evidenziando una forte performance commerciale. YORVIPATH ha raggiunto 908 prescrizioni entro il 7 febbraio 2025, con un fatturato totale per l'anno 2024 di €28,7 milioni. SKYTROFA ha generato circa €202 milioni di fatturato totale per l'anno (escludendo gli aggiustamenti dell'anno precedente).
Il fatturato totale dell'azienda per il 2024 ha raggiunto €363,6 milioni, rispetto ai €266,7 milioni del 2023, trainato dal pagamento anticipato di €91,3 milioni ($100 milioni) da Novo Nordisk e dall'aumento delle vendite di prodotti commerciali. Le spese operative hanno totalizzato €598,1 milioni per il 2024. L'azienda ha riportato una perdita netta di €378,1 milioni (€6,53 per azione) per il 2024.
La posizione di cassa era di €559,5 milioni al 31 dicembre 2024, con ulteriori $100 milioni ricevuti da Novo Nordisk a gennaio 2025. L'azienda prevede di presentare una NDA per TransCon CNP nel primo trimestre del 2025 per il trattamento dell'acondroplasia nei bambini.
Ascendis Pharma (ASND) reportó sus resultados financieros del cuarto trimestre y del año completo 2024, destacando un fuerte desempeño comercial. YORVIPATH alcanzó 908 recetas hasta el 7 de febrero de 2025, con ingresos totales para el año 2024 de €28,7 millones. SKYTROFA generó aproximadamente €202 millones en ingresos totales para el año (excluyendo ajustes del año anterior).
Los ingresos totales de la empresa para 2024 alcanzaron €363,6 millones, frente a €266,7 millones en 2023, impulsados por el pago inicial de €91,3 millones ($100 millones) de Novo Nordisk y por el aumento en las ventas de productos comerciales. Los gastos operativos totalizaron €598,1 millones para 2024. La empresa reportó una pérdida neta de €378,1 millones (€6,53 por acción) para 2024.
La posición de efectivo era de €559,5 millones al 31 de diciembre de 2024, con otros $100 millones recibidos de Novo Nordisk en enero de 2025. La empresa planea presentar una NDA para TransCon CNP en el primer trimestre de 2025 para el tratamiento de la acondroplasia en niños.
Ascendis Pharma (ASND)는 2024년 4분기 및 전체 연도 재무 결과를 발표하며 강력한 상업적 성과를 강조했습니다. YORVIPATH는 2025년 2월 7일까지 908개의 처방을 달성했으며, 2024년 전체 수익은 €28.7백만에 달했습니다. SKYTROFA는 전체 연도 수익으로 약 €202백만을 생성했습니다(이전 연도 조정 제외).
회사의 2024년 총 수익은 €363.6백만에 달하며, 2023년의 €266.7백만에서 증가했습니다. 이는 Novo Nordisk로부터의 €91.3백만($100백만)의 선불 지급과 상업 제품 판매 증가에 힘입은 것입니다. 운영 비용은 2024년 동안 €598.1백만에 달했습니다. 회사는 2024년에 €378.1백만(주당 €6.53)의 순손실을 보고했습니다.
현금 보유액은 2024년 12월 31일 기준으로 €559.5백만이며, 2025년 1월에 Novo Nordisk로부터 추가로 $100백만을 받았습니다. 회사는 2025년 1분기에 아콘드로플라시아 치료를 위한 TransCon CNP에 대한 NDA를 제출할 계획입니다.
Ascendis Pharma (ASND) a publié ses résultats financiers pour le quatrième trimestre et l'année complète 2024, mettant en avant une forte performance commerciale. YORVIPATH a atteint 908 prescriptions d'ici le 7 février 2025, avec un chiffre d'affaires total de 28,7 millions d'euros pour l'année 2024. SKYTROFA a généré environ 202 millions d'euros de chiffre d'affaires pour l'année (hors ajustements de l'année précédente).
Le chiffre d'affaires total de l'entreprise pour 2024 s'est élevé à 363,6 millions d'euros, contre 266,7 millions d'euros en 2023, porté par le paiement initial de 91,3 millions d'euros (100 millions de dollars) de Novo Nordisk et l'augmentation des ventes de produits commerciaux. Les dépenses d'exploitation ont totalisé 598,1 millions d'euros pour 2024. L'entreprise a enregistré une perte nette de 378,1 millions d'euros (6,53 euros par action) pour 2024.
La position de trésorerie s'élevait à 559,5 millions d'euros au 31 décembre 2024, avec un montant supplémentaire de 100 millions de dollars reçu de Novo Nordisk en janvier 2025. L'entreprise prévoit de soumettre une NDA pour TransCon CNP au premier trimestre 2025 pour le traitement de l'achondroplasie chez les enfants.
Ascendis Pharma (ASND) hat seine Finanzzahlen für das vierte Quartal und das Gesamtjahr 2024 veröffentlicht und dabei eine starke kommerzielle Leistung hervorgehoben. YORVIPATH erreichte bis zum 7. Februar 2025 insgesamt 908 Verschreibungen, mit einem Gesamtumsatz von €28,7 Millionen für das Jahr 2024. SKYTROFA erzielte einen Gesamtumsatz von etwa €202 Millionen für das Jahr (ohne Anpassungen des Vorjahres).
Der Gesamtumsatz des Unternehmens für 2024 belief sich auf €363,6 Millionen, ein Anstieg von €266,7 Millionen im Jahr 2023, was auf die Vorauszahlung von €91,3 Millionen ($100 Millionen) von Novo Nordisk und erhöhte Verkaufszahlen von kommerziellen Produkten zurückzuführen ist. Die Betriebsausgaben beliefen sich im Jahr 2024 auf insgesamt €598,1 Millionen. Das Unternehmen berichtete für 2024 einen Nettoverlust von €378,1 Millionen (€6,53 pro Aktie).
Die Liquiditätsreserve betrug zum 31. Dezember 2024 €559,5 Millionen, mit zusätzlichen $100 Millionen, die im Januar 2025 von Novo Nordisk eingegangen sind. Das Unternehmen plant, im ersten Quartal 2025 einen NDA für TransCon CNP zur Behandlung von Achondroplasie bei Kindern einzureichen.
- YORVIPATH launch success with 908 prescriptions and 539 unique prescribing healthcare providers
- SKYTROFA revenue reached €202 million for full year 2024
- Total revenue increased 36% to €363.6 million in 2024
- Strong cash position of €559.5 million plus additional $100 million from Novo Nordisk
- Operating expenses decreased from €677.9 million in 2023 to €598.1 million in 2024
- Net loss of €378.1 million for 2024
- Increased net finance expenses to €74.4 million in 2024 from €0.2 million in 2023
Insights
The financial results reveal a company executing well on its commercial strategy while maintaining strong pipeline momentum. Total revenue of €363.6M represents a
SKYTROFA's performance is particularly noteworthy, generating ~€202M in adjusted full-year revenue. The product has achieved a leading position in the U.S. growth hormone market by value, suggesting strong pricing power and market acceptance. The upcoming PDUFA date for adult growth hormone deficiency could further expand its commercial potential.
YORVIPATH's early launch metrics are encouraging, with 908 prescriptions and 539 unique prescribing healthcare providers, indicating solid initial market penetration. The planned expansion into five additional European countries in 2025, coupled with distribution agreements covering 50+ countries, sets the stage for sustained growth.
Cost management appears effective, with total operating expenses decreasing by
The company's financial position remains robust with €559.5M in cash (€655M including the January 2025 Novo Nordisk payment), providing runway for continued commercial expansion and pipeline development. The upcoming TransCon CNP NDA submission for achondroplasia represents a significant near-term catalyst that could further diversify revenue streams.
– Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of
– Following pre-NDA meeting with FDA, on track to submit TransCon™ CNP NDA for achondroplasia in children in Q1 2025, followed by MAA in Q3 2025
– SKYTROFA® full year 2024 revenue was ~
– Total 2024 operating expenses of
– Conference call today at 4:30 pm ET
COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.
“Having achieved pivotal milestones in 2024, Ascendis is positioned to continue strong revenue growth in 2025 and beyond,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “We believe YORVIPATH is well on its way to establishing itself as the new global standard for the treatment of hypoparathyroidism in adults. SKYTROFA has achieved a leading position in value in the U.S. growth hormone market. And for TransCon CNP, we have a clear path to submit our NDA and MAA as a differentiated treatment of achondroplasia in children. Together with a strong cash balance and established partnerships, I am confident in our ability to become a leading global biopharmaceutical company with multiple blockbuster products and a strong engine for future innovation.”
Select 2024 Highlights & Anticipated 2025 Milestones
- TransCon hGH
(lonapegsomatropin, marketed as SKYTROFA)- SKYTROFA fourth quarter 2024 revenue excluding a positive impact due to reversal of
€4.6 million of sales deductions related to prior years was ~€54 million (fourth quarter reported 2024 SKYTROFA revenue of€58.5 million ). - SKYTROFA full year 2024 revenue excluding
€4.7 million of sales deductions related to prior years was ~€202 million (full year reported 2024 SKYTROFA revenue of€197.0 million ). - Prescription Drug User Fee Act (PDUFA) goal date of July 27, 2025, for FDA review of supplemental BLA for the treatment of adults with growth hormone deficiency; pending approval, U.S. commercial launch planned in the fourth quarter of 2025.
- During the third quarter of 2025, plan to submit an Investigational New Drug (IND) application or similar for a basket trial evaluating TransCon hGH in additional indications.
- SKYTROFA fourth quarter 2024 revenue excluding a positive impact due to reversal of
- TransCon PTH
(palopegteriparatide, marketed as YORVIPATH)- YORVIPATH revenue for the fourth quarter of 2024 totaled
€13.6 million and€28.7 million for the full year 2024, as previously announced. - Strong start to U.S. YORVIPATH launch, with 908 prescriptions as of Feb. 7, 2025, and 539 unique prescribing health care providers.
- Expect commercial launch in at least five additional Europe Direct countries in 2025.
- Eight International Markets exclusive distribution agreements signed covering 50+ countries.
- YORVIPATH revenue for the fourth quarter of 2024 totaled
- TransCon CNP
(navepegritide)- Following pre-NDA meeting with FDA, on track to submit New Drug Application (NDA) for the treatment of achondroplasia in children during the first quarter of 2025, and to submit Marketing Authorisation Application (MAA) to the European Medicines Agency during the third quarter of 2025.
- Presented new data demonstrating additional benefits beyond linear growth, with significant improvements in leg bowing (a common complication in achondroplasia) observed with TransCon CNP compared to worsening observed with placebo in pivotal ApproaCH Trial.
- During the fourth quarter of 2025, plan to submit an IND or similar for the treatment of hypochondroplasia.
- TransCon hGH / TransCon CNP Combination Treatment
- Topline Week 26 results from Phase 2 COACH Trial (TransCon CNP in combination with TransCon hGH) in children with achondroplasia expected in the second quarter of 2025.
- Oncology Program
- Clinical development of TransCon IL-2 β/γ continues, including ongoing investigation of clinical activity in platinum-resistant ovarian cancer (PROC).
- Financial Update
- December 31, 2024, cash and cash equivalents totaling
€559.5 million . - Subsequent to the year end, in January 2025, received
$100 million related to the Exclusive License Agreement with Novo Nordisk announced last year. Including the$100 million upfront payment, cash at the end of 2024 would have totaled€655 million .
- December 31, 2024, cash and cash equivalents totaling
Fourth Quarter and Full Year 2024 Financial Results
Total revenue for the fourth quarter of 2024 was
Total revenue for 2024 was
| Total Revenue (In EUR'000s) | Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Revenue from external customers | ||||||||||||
| Commercial products | 72,130 | 64,249 | 225,728 | 178,663 | ||||||||
| Licenses | 95,853 | 64,304 | 122,343 | 66,077 | ||||||||
| Other | 5,933 | 9,150 | 15,570 | 21,978 | ||||||||
| Total revenue from external customers | 173,916 | 137,703 | 363,641 | 266,718 | ||||||||
| Commercial Product Revenue (In EUR'000s) | Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Revenue from commercial products | ||||||||||||
| SKYTROFA® | 58,546 | 64,249 | 197,001 | 178,663 | ||||||||
| YORVIPATH® | 13,584 | — | 28,727 | — | ||||||||
| Total revenue from commercial products | 72,130 | 64,249 | 225,728 | 178,663 | ||||||||
Research and development (R&D) costs for the fourth quarter of 2024 were
Selling, general, and administrative (SG&A) expenses for the fourth quarter of 2024 were
Total operating expenses for the fourth quarter of 2024 were
Net finance expenses were
For the fourth quarter of 2024, Ascendis Pharma reported a net loss of
As of December 31, 2024, Ascendis Pharma had cash, cash equivalents, and marketable securities totaling
Conference Call and Webcast Information
Ascendis Pharma will host a conference call and webcast today at 4:30 pm Eastern Time (ET) to discuss its fourth quarter and full year 2024 financial results.
Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after conclusion of the event for 30 days.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) the timing of NDA, MAA and IND submissions for TransCon CNP; (ii) Ascendis’ ability to continue strong revenue growth in 2025 and beyond; (iii) YORVIPATH’s ability to become the new global standard for the treatment of hypoparathyroidism in adults; (iv) Ascendis’ ability to become a leading global biopharmaceutical company with multiple blockbuster products and a strong engine for future innovation; (v) the PDUFA goal date for FDA review of SKYTROFA’s supplemental BLA for the treatment of adults with growth hormone deficiency and Ascendis’ plans for a U.S. commercial launch in the fourth quarter of 2025, if approved; (vi) Ascendis’ plan to submit an IND application or similar for a basket trial evaluating TransCon hGH in additional indications; (vii) Ascendis’ expectations with respect to the commercial launch of TransCon PTH in additional countries; (viii) the timing of topline Week 26 data from Phase 2 COACH Trial, the combination TransCon hGH and TransCon CNP trial; (ix) Ascendis’ ability to apply its TransCon technology platform to build a leading, fully integrated biopharma company, and (x) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA®, and YORVIPATH® are trademarks owned by the Ascendis Pharma group.
© February 2025 Ascendis Pharma A/S.
| Investor Contacts: | Media Contact: |
| Scott Smith | Melinda Baker |
| Ascendis Pharma | Ascendis Pharma |
| ir@ascendispharma.com | +1 (650) 709-8875 |
| media@ascendispharma.com | |
| Patti Bank | |
| ICR Healthcare | |
| +1 (415) 513-1284 | |
| patti.bank@icrhealthcare.com |
NEW AND AMENDED IFRS ACCOUTING STANDARDS AND INTERPRETATIONS
The Company has applied amendments to paragraphs 69 to 76 of IAS 1, “Presentation of Financial Statements,” which was effective for annual reporting periods beginning on or after January 1, 2024, and must be applied retrospectively. The amendments to IAS 1 specify the requirements for classifying liabilities as current or non-current. Refer to Note 2 in the financial statements of Ascendis’ Annual Report on Form 20-F for further details.
FINANCIAL TABLES FOLLOW
| Ascendis Pharma A/S Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (In EUR'000s, except share and per share data) | Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Consolidated Statement of Profit or (Loss) | ||||||||||||
| Revenue | 173,916 | 137,703 | 363,641 | 266,718 | ||||||||
| Cost of sales | 14,023 | 19,457 | 44,258 | 44,395 | ||||||||
| Gross profit | 159,893 | 118,246 | 319,383 | 222,323 | ||||||||
| Research and development costs | 79,294 | 90,881 | 307,004 | 413,454 | ||||||||
| Selling, general, and administrative expenses | 80,216 | 63,975 | 291,142 | 264,410 | ||||||||
| Operating profit/(loss) | 383 | (36,610 | ) | (278,763 | ) | (455,541 | ) | |||||
| Share of profit/(loss) of associates | (4,575 | ) | (2,924 | ) | (20,060 | ) | (18,395 | ) | ||||
| Finance income | 26,233 | 22,727 | 25,609 | 43,857 | ||||||||
| Finance expenses | 59,425 | 64,280 | 100,027 | 44,065 | ||||||||
| Profit/(loss) before tax | (37,384 | ) | (81,087 | ) | (373,241 | ) | (474,144 | ) | ||||
| Income taxes (expenses) | (1,085 | ) | (5,791 | ) | (4,843 | ) | (7,303 | ) | ||||
| Net profit/(loss) for the period | (38,469 | ) | (86,878 | ) | (378,084 | ) | (481,447 | ) | ||||
| Attributable to owners of the Company | (38,469 | ) | (86,878 | ) | (378,084 | ) | (481,447 | ) | ||||
| Basic and diluted earnings/(loss) per share | ) | ) | ) | ) | ||||||||
| Number of shares used for calculation (basic and diluted) | 59,785,166 | 56,560,368 | 57,891,570 | 56,287,060 | ||||||||
| Consolidated Statement of Comprehensive Income or (Loss) | ||||||||||||
| Net profit/(loss) for the period | (38,469 | ) | (86,878 | ) | (378,084 | ) | (481,447 | ) | ||||
| Other comprehensive income/(loss) | ||||||||||||
| Items that may be reclassified subsequently to profit or (loss): | ||||||||||||
| Exchange differences on translating foreign operations | 830 | (1,498 | ) | 1,062 | (2,731 | ) | ||||||
| Other comprehensive income/(loss) for the period, net of tax | 830 | (1,498 | ) | 1,062 | (2,731 | ) | ||||||
| Total comprehensive income/(loss) for the period, net of tax | (37,639 | ) | (88,376 | ) | (377,022 | ) | (484,178 | ) | ||||
| Attributable to owners of the Company | (37,639 | ) | (88,376 | ) | (377,022 | ) | (484,178 | ) | ||||
| Ascendis Pharma A/S Consolidated Statements of Financial Position (In EUR'000s) | December 31, 2024 | December 31, 2023 (Restated)* | January 1, 2023 (Restated)* | ||||||
| Assets | |||||||||
| Non-current assets | |||||||||
| Intangible assets | 4,028 | 4,419 | 4,828 | ||||||
| Property, plant and equipment | 98,714 | 110,634 | 129,095 | ||||||
| Investments in associates | 13,575 | 5,686 | 22,932 | ||||||
| Other receivables | 2,317 | 2,127 | 1,920 | ||||||
| Marketable securities | — | — | 7,492 | ||||||
| 118,634 | 122,866 | 166,267 | |||||||
| Current assets | |||||||||
| Inventories | 295,609 | 208,931 | 130,673 | ||||||
| Trade receivables | 166,280 | 35,874 | 11,910 | ||||||
| Income tax receivables | 1,775 | 802 | 883 | ||||||
| Other receivables | 9,385 | 19,097 | 12,833 | ||||||
| Prepayments | 28,269 | 38,578 | 31,717 | ||||||
| Marketable securities | — | 7,275 | 290,688 | ||||||
| Cash and cash equivalents | 559,543 | 392,164 | 444,767 | ||||||
| 1,060,861 | 702,721 | 923,471 | |||||||
| Total assets | 1,179,495 | 825,587 | 1,089,738 | ||||||
| Equity and liabilities | |||||||||
| Equity | |||||||||
| Share capital | 8,149 | 7,749 | 7,675 | ||||||
| Distributable equity | (113,855 | ) | (153,446 | ) | 255,673 | ||||
| Total equity | (105,706 | ) | (145,697 | ) | 263,348 | ||||
| Non-current liabilities | |||||||||
| Borrowings | 365,080 | 222,996 | 95,400 | ||||||
| Contract liabilities | 5,000 | 5,949 | 14,213 | ||||||
| Deferred tax liabilities | 7,258 | 5,830 | — | ||||||
| 377,338 | 234,775 | 109,613 | |||||||
| Current liabilities | |||||||||
| Convertible notes, matures in April 2028 | |||||||||
| Borrowings | 458,207 | 407,095 | 399,186 | ||||||
| Derivative liabilities | 150,670 | 143,296 | 157,950 | ||||||
| 608,877 | 550,391 | 557,136 | |||||||
| Other current liabilities | |||||||||
| Borrowings | 33,329 | 14,174 | 13,791 | ||||||
| Contract liabilities | 936 | 1,184 | — | ||||||
| Trade payables and accrued expenses | 96,394 | 94,566 | 101,032 | ||||||
| Other liabilities | 67,956 | 41,176 | 31,989 | ||||||
| Income tax payables | 1,222 | 2,299 | 5,490 | ||||||
| Provisions | 99,149 | 32,719 | 7,339 | ||||||
| 298,986 | 186,118 | 159,641 | |||||||
| 907,863 | 736,509 | 716,777 | |||||||
| Total liabilities | 1,285,201 | 971,284 | 826,390 | ||||||
| Total equity and liabilities | 1,179,495 | 825,587 | 1,089,738 | ||||||
| *Restatement relates to adoption of amendments to IAS 1 “Presentation of Financial Statements.” | |||||||||
| Refer to Note 2 in the financial statements of Ascendis’ Annual Report on Form 20-F for further details. | |||||||||
FAQ
What was Ascendis Pharma's (ASND) revenue for full year 2024?
How many YORVIPATH prescriptions did ASND achieve by February 2025?
What was SKYTROFA's revenue performance in 2024?
When will Ascendis submit the TransCon CNP NDA for achondroplasia treatment?
What is Ascendis Pharma's current cash position as of December 2024?
